文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

开发一种主动监测或手术模型,以预测 cN0 期甲状腺微小乳头状癌的淋巴结转移。

Development of an Active Surveillance or Surgery Model to Predict Lymph Node Metastasis in cN0 Papillary Thyroid Microcarcinoma.

机构信息

Cancer Prevention Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.

Department of Head and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.

出版信息

Front Endocrinol (Lausanne). 2022 Jul 22;13:896121. doi: 10.3389/fendo.2022.896121. eCollection 2022.


DOI:10.3389/fendo.2022.896121
PMID:35937812
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9353015/
Abstract

OBJECTIVE: Involvement of multiple lymph node (LN) metastasis in papillary thyroid microcarcinoma (PTMC) may indicate a progressive disease. To assist treatment decision, we conducted a clinical study to develop and validate a prediction model for the preoperative evaluation of LN metastasis involving more than five lymph nodes in patients with clinical N0 (cN0) PTMC. MATERIAL AND METHODS: Using data from 6,337 patients with cN0 PTMCs at Tianjin Medical University Cancer Institute and Hospital from 2013 to 2017, we identified and integrated risk factors for the prediction of multiple LN metastasis to build a nomogram. The predictive accuracy and discriminative ability of the nomogram were evaluated by the concordance index (C-index) and calibration curve. The model was validated using bootstrap resampling of the training cohort and an independent temporal validation cohort at the same institution. RESULTS: In the training cohort (n = 3,209 patients), six independent risk factors were identified and included the prediction model (PTMC Active Surveillance or Surgery (ASOS) Model), including age, gender, multifocality, tumor size, calcification, and aspect ratio. The PTMC ASOS model was validated both internally and through the temporal validation cohort (n = 3,128 patients) from the same institute. The C-indexes of the prediction model in the training cohort were 0.768 (95% CI, 0.698-0.838), 0.768 and 0.771 in the internal validation and external validation cohorts, respectively. The area under the receiver operating characteristic curve (AUC) was 0.7068 and 0.6799. The calibration curve for probability of large-LN metastasis showed good agreement between prediction by nomogram and actual observation. DCA curves were used for comparison with another model, and IDI and NRI were also calculated. The cutoff value of our model was obtained by the ROC curve. Based on this model and cut point, a web-based dynamic nomogram was developed (https://tjmuch-thyroid.shinyapps.io/PTMCASOSM/). CONCLUSION: We established a novel nomogram that can help to distinguish preoperatively cN0 PTMC patients with or without metastasis of multiple lymph nodes. This clinical prediction model may be used in decision making for both active surveillance and surgery.

摘要

目的:甲状腺乳头状微小癌(PTMC)中多个淋巴结(LN)转移的参与可能表明疾病进展。为了辅助治疗决策,我们进行了一项临床研究,以开发和验证用于预测临床 N0(cN0)PTMC 患者术前 LN 转移超过五个淋巴结的模型。

材料和方法:使用 2013 年至 2017 年天津医科大学肿瘤医院 6337 例 cN0 PTMC 患者的数据,我们确定并整合了多个 LN 转移预测的风险因素,以构建列线图。通过一致性指数(C-index)和校准曲线评估列线图的预测准确性和判别能力。使用训练队列的 bootstrap 重采样和同一机构的独立时间验证队列对模型进行验证。

结果:在训练队列(n=3209 例)中,确定了 6 个独立的危险因素,并包含预测模型(PTMC 主动监测或手术(ASOS)模型),包括年龄、性别、多灶性、肿瘤大小、钙化和纵横比。PTMC ASOS 模型在内部和同一机构的时间验证队列(n=3128 例)中均得到验证。预测模型在训练队列中的 C 指数分别为 0.768(95%CI,0.698-0.838)、0.768 和 0.771。受试者工作特征曲线(AUC)下面积分别为 0.7068 和 0.6799。大淋巴结转移概率的校准曲线显示了列线图预测与实际观察之间的良好一致性。DCA 曲线用于与另一个模型进行比较,并计算了 IDI 和 NRI。我们的模型的截止值是通过 ROC 曲线获得的。基于该模型和切点,开发了一个基于网络的动态列线图(https://tjmuch-thyroid.shinyapps.io/PTMCASOSM/)。

结论:我们建立了一种新的列线图,可以帮助区分术前 cN0 PTMC 患者是否存在多个淋巴结转移。该临床预测模型可用于主动监测和手术的决策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/404d/9353015/ad6c58ae8140/fendo-13-896121-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/404d/9353015/beb62c6b2157/fendo-13-896121-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/404d/9353015/cce6ff8bf30c/fendo-13-896121-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/404d/9353015/037b51c40abc/fendo-13-896121-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/404d/9353015/bca84d122d21/fendo-13-896121-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/404d/9353015/7c3e1cad9575/fendo-13-896121-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/404d/9353015/b74074ece1d8/fendo-13-896121-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/404d/9353015/ad6c58ae8140/fendo-13-896121-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/404d/9353015/beb62c6b2157/fendo-13-896121-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/404d/9353015/cce6ff8bf30c/fendo-13-896121-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/404d/9353015/037b51c40abc/fendo-13-896121-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/404d/9353015/bca84d122d21/fendo-13-896121-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/404d/9353015/7c3e1cad9575/fendo-13-896121-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/404d/9353015/b74074ece1d8/fendo-13-896121-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/404d/9353015/ad6c58ae8140/fendo-13-896121-g007.jpg

相似文献

[1]
Development of an Active Surveillance or Surgery Model to Predict Lymph Node Metastasis in cN0 Papillary Thyroid Microcarcinoma.

Front Endocrinol (Lausanne). 2022

[2]
The model for predicting the central lymph node metastasis in cN0 papillary thyroid microcarcinoma with Hashimoto's thyroiditis.

Front Endocrinol (Lausanne). 2024

[3]
Web-Based Ultrasonic Nomogram Predicts Preoperative Central Lymph Node Metastasis of cN0 Papillary Thyroid Microcarcinoma.

Front Endocrinol (Lausanne). 2021

[4]
Development of a nomogram for prediction of central lymph node metastasis of papillary thyroid microcarcinoma.

BMC Cancer. 2024-2-20

[5]
A nomogram based on ultrasound radiomics for predicting the invasiveness of cN0 single papillary thyroid microcarcinoma.

Gland Surg. 2023-12-26

[6]
A clinical and molecular pathology prediction model for central lymph node metastasis in cN0 papillary thyroid microcarcinoma.

Front Endocrinol (Lausanne). 2023

[7]
Nomogram for Preoperative Estimation of Cervical Lymph Node Metastasis Risk in Papillary Thyroid Microcarcinoma.

Front Endocrinol (Lausanne). 2021

[8]
Clinical and ultrasonic risk factors for high-volume central lymph node metastasis in cN0 papillary thyroid microcarcinoma: A retrospective study and meta-analysis.

Clin Endocrinol (Oxf). 2023-4

[9]
Development and Validation of a Computed Tomography-Based Radiomics Nomogram for the Preoperative Prediction of Central Lymph Node Metastasis in Papillary Thyroid Microcarcinoma.

Acad Radiol. 2024-5

[10]
Clinicopathologic factors and preoperative ultrasonographic characteristics for predicting central lymph node metastasis in papillary thyroid microcarcinoma: a single center retrospective study.

Braz J Otorhinolaryngol. 2022

引用本文的文献

[1]
Mapping the lymph node metastasis landscape: A bibliometric Odyssey of papillary thyroid carcinoma publications (2012-2022).

Heliyon. 2024-5-16

[2]
A prediction model for identifying high-risk lymph node metastasis in clinical low-risk papillary thyroid microcarcinoma.

BMC Endocr Disord. 2023-11-27

[3]
The role of multifocality in predicting central lymph node metastasis in initially treated 18-55 years old female patients with unilateral papillary thyroid microcarcinoma.

Front Oncol. 2023-8-31

本文引用的文献

[1]
Molecular Imaging and Theragnostics of Thyroid Cancers.

Cancers (Basel). 2022-3-1

[2]
Increasing Gap Between Thyroid Cancer Incidence and Mortality in Urban Shanghai, China: An Analysis Spanning 43 Years.

Endocr Pract. 2021-11

[3]
Nomogram for Preoperative Estimation of Cervical Lymph Node Metastasis Risk in Papillary Thyroid Microcarcinoma.

Front Endocrinol (Lausanne). 2021

[4]
Adoption of Active Surveillance for Very Low-Risk Differentiated Thyroid Cancer in the United States: A National Survey.

J Clin Endocrinol Metab. 2021-3-25

[5]
Indications and Strategy for Active Surveillance of Adult Low-Risk Papillary Thyroid Microcarcinoma: Consensus Statements from the Japan Association of Endocrine Surgery Task Force on Management for Papillary Thyroid Microcarcinoma.

Thyroid. 2021-2

[6]
2020 Chinese guidelines for ultrasound malignancy risk stratification of thyroid nodules: the C-TIRADS.

Endocrine. 2020-11

[7]
Development and validation of a nomogram for preoperative prediction of cervical lymph node involvement in thyroid microcarcinoma.

Aging (Albany NY). 2020-3-13

[8]
Predicting large-volume lymph node metastasis in the clinically node-negative papillary thyroid microcarcinoma: a retrospective study.

Nucl Med Commun. 2020-1

[9]
Long-term oncologic outcomes of papillary thyroid microcarcinoma according to the presence of clinically apparent lymph node metastasis: a large retrospective analysis of 5,348 patients.

Cancer Manag Res. 2018-8-27

[10]
A clinical framework to facilitate selection of patients with differentiated thyroid cancer for active surveillance or less aggressive initial surgical management.

Expert Rev Endocrinol Metab. 2018-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索